Characteristic | HFNC failure (N=59) | HFNC success (N=41) |
Age (median) | 66 | 68 |
Race (n, %) | ||
African American | 50 (85%) | 38 (93%) |
Caucasian | 4 (7%) | 0 (0%) |
Gender (n, %) | ||
Male | 35 (59%) | 22 (54%) |
Female | 24 (41%) | 19 (46%) |
BMI (n, %) | ||
<18.5 | 1 (2%) | 2 (5%) |
18.5–24.9 | 7 (12%) | 10 (24%) |
25–29.9 | 21 (36%) | 8 (20%) |
30–39.9 | 19 (32%) | 14 (34%) |
>40 | 10 (17%) | 6 (15%) |
Comorbidities | ||
Hypertension (n, %) | 41 (69%) | 34 (83%) |
Diabetes (n, %) | 20 (34%) | 15 (37%) |
Lung disease (n, %) | 19 (32%) | 9 (22%) |
Heart disease (n, %) | 19 (32%) | 14 (34%) |
Kidney disease (n, %) | 16 (27%) | 8 (20%) |
Cancer (n, %) | 4 (7%) | 2 (5%) |
Admission characteristics | ||
FiO2 (median) | 21% | 21% |
SpO2 (median) | 91% | 93% |
CRP (median) | 160 | 143 |
LDH (median) | 573 | 414 |
Ferritin (median) | 693 | 744 |
CPK (median) | 233 | 249 |
Troponin (median) | 31 | 38 |
D-dimer (median) | 1.96 | 2.00 |
Lymphocyte count (median) | 900 | 900 |
Hospital course | ||
Hepatic dysfunction (n, %) | 23 (39%) | 4 (10%) |
Troponemia (n, %) | 21 (36%) | 9 (22%) |
Kidney injury (n, %) | 49 (83%) | 18 (44%) |
INR dysfunction (n, %) | 16 (27%) | 3 (7%) |
Received steroids (n, %) | 45 (76%) | 29 (71%) |
Received HCQ (n, %) | 51 (86%) | 29 (71%) |
ABG pH prior to HFNC (median) | 7.423 | 7.428 |
ABG pO2 prior to HFNC (median) | 58.6 | 65.3 |
mSOFA prior to HFNC (median) | 5 | 5 |
Ventilator free days (mean) | 3.1 | 19.0 |
Sixty-day mortality (n, %) | 41 (69%) | 11 (27) |
ABG, arterial blood gas; BMI, body mass index; CPK, creatine phosphokinase; CRP, C reactive protein; HCQ, hydroxychloroquine; HFNC, high-flow nasal cannula; INR, international normalised ratio; LDH, lactate dehydrogenase; mSOFA, modified sequential organ failure score.